We are live on ! Find out more
VM

VHCP Management Portfolio holdings

AUM $93M
1-Year Est. Return 10.04%
This Fund
S&P 500
This Quarter Est. Return
+6.48%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$223M
AUM Growth
+$35.4M
Cap. Flow
+$30.9M
Cap. Flow %
13.9%
Top 10 Hldgs %
88.92%
Holding
19
New
2
Increased
2
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$41.1M
2
LPCN icon
Lipocine
LPCN
+$3.86M
3
STML
Stemline Therapeutics, Inc.
STML
+$874K

Top Sells

Rank Stock Value
1
KERX
Keryx Biopharmaceuticals Inc
KERX
+$10.8M
2
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$7.47M
3
ALXA
Alexza Pharmaceuticals Inc
ALXA
+$674K

Sector Composition

Rank Sector Weight
1 Healthcare 64.27%
2 Miscellaneous 35.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADVM
1
DELISTED
Adverum Biotechnologies
ADVM
$42.8M 19.25%
+138,274
New +$41.1M
ANAC
2
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$28.8M 12.96%
1,178,474
-367,525
-24% -$7.47M
GWPH
3
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$25.2M 11.33%
311,853
– –
DYAX
4
DELISTED
DYAX CORPORATION
DYAX
$20.2M 9.1%
2,000,859
– –
BCRX icon
5
BioCryst Pharmaceuticals
BCRX
$2.52B
$17.1M 7.67%
1,744,356
– –
RDUS
6
DELISTED
Radius Health, Inc.
RDUS
$11M 4.95%
525,000
– –
LRMR icon
7
Larimar Therapeutics
LRMR
$421M
$10M 4.5%
45,123
– –
HRTX icon
8
Heron Therapeutics
HRTX
$63M
$9.13M 4.1%
1,095,734
– –
AVDL
9
DELISTED
Avadel Pharmaceuticals
AVDL
$7.16M 3.22%
500,000
– –
NBIX icon
10
Neurocrine Biosciences
NBIX
$15.8B
$4.76M 2.14%
303,503
– –
LPCN icon
11
Lipocine
LPCN
$18.4M
$4.09M 1.84%
39,407
+31,048
+371% +$3.86M
TXMD icon
12
TherapeuticsMD
TXMD
$25.7M
$3.93M 1.77%
16,930
– –
ZSPH
13
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$3.92M 1.76%
100,000
– –
NBSE
14
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$3.46M 1.55%
1,193
– –
OCRX
15
DELISTED
Ocera Therapeutics, Inc.
OCRX
$3.45M 1.55%
703,730
– –
STML
16
DELISTED
Stemline Therapeutics, Inc.
STML
$884K 0.4%
+71,000
New +$874K
ALXA
17
DELISTED
Alexza Pharmaceuticals Inc
ALXA
$166K 0.07%
71,212
-176,600
-71% -$674K
KERX
18
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-700,273
Closed -$10.8M

Similar funds

QGI
Quadrangle GP Investors New York $93.6M AUM 10.64% 1-Year Est. Return
KC
Kanha Capital New York $89.9M AUM
RSCM
Rail-Splitter Capital Management Chicago, Illinois $89.4M AUM 15.13% 1-Year Est. Return
ZC
Zelman Capital Beachwood, Ohio $81.9M AUM 22.32% 1-Year Est. Return
TF
Trutina Financial Bellevue, Washington $76.7M AUM 19.34% 1-Year Est. Return
SAM
Sunnymeath Asset Management Red Bank, New Jersey $71.2M AUM 26.57% 1-Year Est. Return
NA
NS Advisors Westport, Connecticut $71M AUM 25.21% 1-Year Est. Return
NCIM
New Century Investment Management Southfield, Michigan $70.5M AUM 23.2% 1-Year Est. Return

VHCP Management's Q3 2014 Portfolio in Review

As of Q3 2014, VHCP Management held 19 positions worth $223M, up 19% from $187M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

VHCP Management deployed $30.9M of net new capital in Q3 2014, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Adverum Biotechnologies: 138,274 shares worth $42.8M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 66% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was ANACOR PHARMACEUTICALS INC COM, an estimated $7.47M trimmed.

  • VHCP Management's largest Q3 2014 buy was Adverum Biotechnologies: 138,274 shares worth $42.8M.
  • VHCP Management added most to Lipocine in Q3 2014, an estimated $3.86M increase.
  • VHCP Management's biggest Q3 2014 reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $7.47M.
  • VHCP Management fully exited Keryx Biopharmaceuticals Inc in Q3 2014, selling an estimated $10.8M.
  • VHCP Management's ten largest holdings make up 89% of its $223M portfolio in Q3 2014.
  • VHCP Management opened 2 new positions and closed 1 in Q3 2014.
  • VHCP Management's portfolio value rose 19% quarter-over-quarter to $223M.

Based on VHCP Management's 13F filing for Q3 2014, filed 13 Nov 2014.